Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging prelimiray data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.

Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension / M. Guazzi, M. Gomberg-Maitland, R. Naeije. - In: PROGRESS IN CARDIOVASCULAR DISEASES. - ISSN 0033-0620. - 57:5(2015), pp. 473-479. [Epub ahead of print] [10.1016/j.pcad.2014.11.002]

Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension

M. Guazzi
Primo
;
2015

Abstract

Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging prelimiray data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.
CHD; Coronary heart disease; Cyclic guanylate cyclase; ET1; Endothelin 1; Endothelin-1 receptor blockers; HF; HR; HTX; Heart failure; Heart rate; LV; LVAD-LV; Left ventricle or ventricular; NO; Nitric oxide; Nitrous or nitric oxide; PAP; PCWP; PDE; PDE-5 inhibitors; PH; PVR; Phosphodiesterase; Prostaglandins; Pulmonary artery pressure; Pulmonary capillary wedge pressure; Pulmonary hypertension; Pulmonary or pulmonary artery hypertension; Pulmonary vascular resistance; Pulmonary vasodilators; RAP; RV; Right atrial pressure; Right ventricle or ventricular; Soluble guanylate cyclase; VHD; Valvular heart disease; assist device; cGMP; guanylate cyclase stimulators; heart or cardiac transplantation; pEF -Preserved ejection fraction; sGC
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0033062014001704-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 369.54 kB
Formato Adobe PDF
369.54 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/255520
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact